66th ASH Annual Meeting: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents

Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Clinical trials, Research, Apoptosis, MDS, MPN, Drug development, Clinical Research, Chronic Myeloid Malignancies, Diseases, Treatment Considerations, Myeloid Malignancies, Measurable Residual Disease

Grand Hall C (Manchester Grand Hyatt San Diego)

Moderators:

John O. Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai and Lynda Foltz, MD, University of British Columbia

Disclosures:

No relevant conflicts of interest to declare.

This session focuses on latest breakthroughs in the treatment and management of MPNs, with an emphasis on innovative JAK inhibitors and novel therapies specifically for myelofibrosis and systemic mastocytosis. The presentations will cover first-in-human trials and advanced studies of next-generation treatments offering new hope for patients with myelofibrosis and other MPNs, particularly those who are refractory or intolerant to current therapies. Additionally, the session will explore prognostic implications of pulmonary hypertension in MPNs and its role in predicting hematologic progression.

This session aims to provide healthcare professionals with cutting-edge knowledge on emerging therapies and key prognostic factors, equipping them to enhance patient outcomes and refine treatment strategies in the evolving landscape of MPN care.

9:30 AM

481

A Phase 2 Study of Fedratinib in Patients with MDS/MPN and Chronic Neutrophilic Leukemia

Andrew T. Kuykendall, MD¹, Tania Jain, MD², Abhay Singh, MD, MPH³, Kristen M. Pettit, MD⁴, Quan Lovette⁵^*, Joan McFadden Cain, BSN, RN⁶^*, Tracy Ann Cinalli, RN⁷^*, Mary Gallagher, RN⁸^*, David Sallman, MD¹, Qianxing Mo, PhD⁵^*, Ling Zhang, MD⁹^*, Onyee Chan, MD¹⁰, Alison R. Walker, MD, MBA, MPH¹, Zhuoer Xie, MD, MS¹, Jeffrey E Lancet, MD¹, Maria Balasis⁵^*, Seongseok Yun, MD, PhD¹, Eric Padron, MD¹¹ and Rami S. Komrokji, MD¹

¹Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
³Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁴Rogel Cancer Center, University of Michigan, Ann Arbor, MI
⁵Moffitt Cancer Center, Tampa, FL
⁶Johns Hopkins, Baltimore, MD
⁷Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁸University of Michigan, Ann Arbor, MI
⁹Hematopathology and Laboratory Medicine, Moffitt Cancer Center & Research Institute, Tampa, FL
¹⁰Department of Malignant Hematology, University of Arizona, Banner University Medical Center-Tucson, Tampa, FL
¹¹Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL

9:45 AM

482

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Haifa Kathrin Al-Ali, MD; PhD¹^*, Claire Harrison², Ruben Mesa, MD³^*, Moshe Talpaz, MD⁴, Blanca Xicoy, MD⁵^*, Francesco Passamonti, MD⁶^*, Alessandro Vannucchi⁷^*, Patrick Brown⁸^*, Christopher Hernandez⁸^*, Jia Wang⁸^*, Jun He⁹^* and Jean-Jacques Kiladjian, MD, PhD¹⁰

¹Universitätsklinikum Halle, Saale, Germany
²Guy's and St Thomas’ NHS Foundation Trust, London, United Kingdom
³Wake Forest University School of Medicine, Winston-Salem, NC
⁴University of Michigan Cancer Center, Ann Arbor, MI
⁵Institut Català d’Oncologia-Hospital Universitari Germans Trias i Pujol (HUGTP) -Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
⁶Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
⁷A.O.U. Careggi, Universita di Firenze, Florence, Italy
⁸Bristol Myers Squibb, Princeton, NJ
⁹Bristol Myers Squibb, Giralda Farms, NJ
¹⁰Hospital Saint Louis and University Paris Cité, Paris, France

10:00 AM

483

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, MD¹, Prithviraj Bose, MD², Hsin-An Hou, MD, PhD, MSc³^*, Wojciech Homenda, MD, PhD⁴^*, David Ross, MD⁵^*, Sanjay R Mohan, MD, MSc⁶, Jean-Jacques Kiladjian, MD, PhD⁷, Haifa Kathrin Al-Ali, MD; PhD⁸^*, Andrew Charles Perkins, MBBS, PhD⁹, Yulia Khalina, BSc¹⁰^*, Tracy Clevenger, PhD¹⁰^*, Zhuying Huang, PhD¹⁰^*, Jesse McGreivy, MD¹⁰^*, Wayne Rothbaum, MS¹⁰^*, Srdan Verstovsek, MD, PhD¹⁰ and Alessandro M. Vannucchi, MD¹¹

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
⁴Department of Hematology and Bone Marrow Transplantation, Pomeranian University, Slupsk, Poland
⁵Royal Adelaide Hospital and SA Pathology, Adelaide, Australia
⁶The Vanderbilt Clinic, Nashville, TN
⁷Hopital Saint-Louis, Paris, France
⁸University Hospital Halle, Halle (Saale), Germany
⁹The Alfred Hospital and Monash University, Melbourne, Australia
¹⁰Kartos Therapeutics, Inc., Redwood City, CA
¹¹University of Florence, Florence, Italy

10:15 AM

484

Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

Chunkang Chang, MD¹^*, Min Zhang²^*, Sujun Gao³^*, Luxi Song⁴^*, Duoer Wu⁴^*, Dawei Ding⁵^*, Shanli Lao⁵^* and Ding Yu⁵^*

¹Hematology department, Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai, China
²Department of Haematology, Institute of Hematology, Union Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, China
³The First Hospital of Jilin University, Changchun, China
⁴Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai, China
⁵Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Nanjing, China

10:30 AM

485

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Zi Yun Ng, MBBS¹, Laurane Cottin²^*, Damien Luque Paz²^*, Corentin Orvain²^*, Kamel Laribi³^*, Jean-Christophe Ianotto⁴^*, Eric Lippert⁵^*, Alesia Khan⁶^*, Daniel Lock⁶^*, Valerie Ugo⁷^*, Claire Harrison⁸ and Jennifer O'Sullivan^9,10^*

¹Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
²Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
³Hématologie Clinique, CH Le Mans, Le Mans, France
⁴Service d’Hématologie et d’Hémostase clinique, Institut de Cancérologie et Hématologie, CHU de Brest, Brest, France
⁵Service d’Hématologie biologique, Hôpital de la Cavale Blanche, CHU de Brest, Brest, France
⁶Haematological Malignancy Diagnostic Service, Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom
⁷Université Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Angers, France
⁸Guy's and St Thomas' NHS Foundation Trust, London, ENG, United Kingdom
⁹Department of Haematology, Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
¹⁰Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM) and NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

10:45 AM

486

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Lijuan Chen^1,2^*, Yongsheng Wang¹^*, Jie Wang¹^*, Linyu Yang^1,2^* and Ting Niu^1,2,3

¹Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
²State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
³National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University, Chengdu, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

634.O1.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents